Company
Headquarters: Beijing, China
Employees: 835
CN¥13.76 Billion
CNY as of Jan. 1, 2026
US$1.96 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; gene therapy/cell therapy drugs; and chemical drugs. It principally offers its products under the fields of nervous system related, infectious, gastrointestinal, urinary system, and autoimmune diseases. The company has a strategic collaboration with Pivotal S.L. to assess BDB-001, a monoclonal anti-C5a antibody, in a clinical trial in Europe in progressive severe COVID-19 patients caused by SARS-CoV-2. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CN¥244.4 M |
| EBITDA | CN¥-56,803,960 |
| Gross Profit TTM | CN¥190.6 M |
| Profit Margin | -68.00% |
| Operating Margin | -9.66% |
| Quarterly Revenue Growth | -30.10% |
Staidson has the following listings and related stock indices.
Stock: SZSE: 300204 wb_incandescent